Latest news in cancer
Selpercatinib is approved by FDA for RET fusion-positive thyroid cancer
May 2024: The Food and Drug Administration has officially approved selpercatinib (Retevmo, Eli Lilly and Company) for the treatment of advanced or...
Imetelstat is approved by FDA for low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia
May 2024: Imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, has been approved by the Food and Drug Administration for use...
Lisocabtagene maraleucel is approved by FDA for relapsed or refractory mantle cell lymphoma
Lisocabtagene maraleucel, a CAR T-cell therapy, has been approved by the FDA for the treatment of adults with relapsed or refractory mantle cell lymphoma. This...
Tarlatamab-dlle is granted accelerated approval by FDA for extensive stage small cell lung cancer
May 2024: Tarlatamab-dlle (Imdelltra, Amgen, Inc.) has received fast approval from the Food and Drug Administration for the treatment of extensive stage small...
Lisocabtagene maraleucel is granted accelerated approval by FDA for follicular lymphoma
The FDA has granted accelerated approval to Lisocabtagene maraleucel for treating follicular lymphoma. This CAR T-cell therapy targets the CD19 antigen on...
Tisotumab vedotin-tftv is approved by the FDA for recurrent or metastatic cervical cancer
Tisotumab Vedotin-tftv has been approved by the FDA for treating recurrent or metastatic cervical cancer. This antibody-drug conjugate targets tissue factor,...
Tovorafenib has been granted accelerated approval by the FDA for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma
Tovorafenib has received accelerated approval from the FDA for treating relapsed or refractory BRAF-altered pediatric low-grade glioma. This approval offers...
Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study
CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause...
Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
Seattle Children's Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body's...
Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy...
Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report
Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This...
What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?
For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR...
CARSgen presents latest data of Satri-cel therapy in ASCO 2024
At ASCO 2024, CARSgen unveiled new data on Satri-cel, their promising CAR-T cell therapy for cancer treatment. The latest findings highlighted significant...
Can CAR T cell therapy shortcomings be avoided by NK Cell therapy?
NK Cell therapy vs CAR T-Cell therapy The FDA’s approval of the first CAR T cell therapy in 2017 was widely celebrated as a significant advancement in...
CAR T Cell therapy for refractory systemic lupus erythematosus in China
CAR T cell therapy has emerged as a promising treatment for refractory systemic lupus erythematosus (SLE) in China. This innovative approach involves...
Zevorcabtagene autoleucel (Zevra-cel therapy) approved for R/R multiple myeloma
SHANGHAI, China, April 30, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the...
After amazing growth of CAR T-Cell therapy: what’s next?
CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient's T-cells to attack cancer cells, demonstrating remarkable success in...
Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients,...
Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
"Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach...
Alectinib has been approved by the USFDA as adjuvant treatment for ALK-positive non-small cell lung cancer
The FDA's recent approval of alectinib marks a significant advancement in the treatment landscape for ALK-positive non-small cell lung cancer (NSCLC). As an...
NMPA approves zevorcabtagene autoleucel CAR T Cell therapy for R/R multiple myeloma
Zevor-Cel therapy Chinese regulators have approved zevorcabtagene autoleucel (zevor-cel; CT053), an autologous CAR T-cell therapy, for the treatment of adult...
Understanding BCMA: A Revolutionary Target in Cancer Treatment
Introduction In the ever-evolving realm of oncological treatment, scientists persistently seek out unconventional targets that can amplify the effectiveness of...
Human-Based CAR T Cell Therapy: Breakthroughs and Challenges
Human-based CAR T-cell therapy revolutionizes cancer treatment by genetically modifying a patient's own immune cells to target and destroy cancer cells. By...
Understanding Cytokine Release Syndrome: Causes, Symptoms, and Treatment
Cytokine Release Syndrome (CRS) is an immune system reaction often triggered by certain treatments like immunotherapy or CAR-T cell therapy. It involves an...
Role of paramedics in the success of CAR T Cell therapy
Paramedics play a crucial role in the success of CAR T-cell therapy by ensuring seamless patient care throughout the treatment process. They provide vital...
How Targeted Therapy is Revolutionizing Advanced Cancer Treatment?
In the field of oncology, the emergence of targeted therapy has revolutionized the treatment landscape for advanced cancers. Unlike conventional chemotherapy,...
Utilizing Immunotherapy to Treat Late-Stage Cancers
Introduction Immunotherapy has become a groundbreaking method in cancer treatment, especially for advanced-stage cancer treatments that have...
Survivorship and long-term care in advanced cancers
Dive into the complexities of survivorship and long-term care for individuals facing advanced cancers. Discover the latest advancements in care coordination...
FasTCAR-T GC012F demonstrated overall 100% response rate in newly diagnosed multiple myeloma
Introduction Even in transplant-eligible (TE) patients, typical first-line treatments for high-risk (HR) newly-diagnosed multiple myeloma (NDMM) have dismal...
CAR T Cell therapy for AIDS related B-Cell malignancies
CAR T cell therapy for HIV-related B cell malignancies involves genetically modifying a patient's T cells to express chimeric antigen receptors (CARs)...
Cancer statistics in India 2024: Incidence, estimates and projections
In 2024, cancer will remain a significant health challenge in India. The country sees over 1.5 million new cases a year. Breast and oral cancers are most...
India declared cancer capital of the world – Apollo report
India declared cancer capital of the world India was designated as the “cancer capital of the world” in the 4th edition of Apollo Hospitals’...
Mirvetuximab soravtansine-gynx is approved by the USFDA for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
March 2024: The Food and Drug Administration has granted approval for mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) to be...
Ponatinib with chemotherapy has received accelerated approval by the USFDA for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
March 2024: Ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) has received fast approval from the Food and Drug Administration for use in combination...
Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma
March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug...
Nivolumab in combination with cisplatin and gemcitabine is approved by the USFDA for unresectable or metastatic urothelial carcinoma
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.